C-Path’s TRxA Announces $750,000 in Research Awards to Accelerate its First Drug Development Projects

TUCSON, Ariz., June 28, 2023 — Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) announced today its first two research grants supporting academic scientists in advancing novel compounds through the drug development process. Launched in June 2022, TRxA is a global drug discovery and development program focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics, from the lab to patientsContinue reading

New Data Predicts Impacts of the IRA on the Health Innovation Ecosystem

This Vital Health Podcast was recorded at the BIO international Conference on the afternoon of the release of Vital Transformation’s research study outlining the impacts of the Inflation Reduction Act on U.S. biopharma innovation. It features Duane Schulthess, Nick Shipley, the Executive Vice President of BIO, and Joe Hammang, Vital Transformation’s U.S. Business Director.Continue reading

Langham Upgrades Phoenix GMP Warehouse, CRT Expansion

INDIANAPOLIS—Langham Logistics, an Indiana-based warehousing and transportation company with a focus in life sciences, today announced an adaptation of the second half of its Arizona building to GMP controlled room space. More than 9,000 newly-converted controlled room temperature (CRT) pallet positions opened for full operations on June 1st to serve the West Coast’s cold chain warehousing and distribution demands.Continue reading

Single-Cell Atlas of the Whole Human Lung

First integrated Human Lung Cell Atlas provides insights into lung diseases.

By combining data from nearly 40 studies, an international team of researchers, including TGen’s Dr. Nicholas Banovich, created the first integrated single-cell atlas of the lung, revealing rare cell types and highlighting cellular differences between healthy people. In addition, the study found common cell states between lung fibrosis, cancer and COVID-19, offering new ways of understanding lung disease, which could help identify new therapeutic targets.

Continue reading

CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B

HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus standard of care, and reduce or eliminate the need for prophylactic treatment in 94% of patients (51 out of 54) after a one-time infusionContinue reading

CSBI Releases the 2023 Life Sciences Workforce Trends Report at BIO International Convention

BOSTON, MASS., U.S.A., June 7, 2023/EINPresswire.com/ — The Coalition of State Bioscience Institutes (CSBI) releases the 2023 Life Sciences Workforce Trends Report with TEConomy Partners this week at the 2023 BIO International Convention in Boston. The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.Continue reading